erythro-5-Phosphooxy-L-lysine|CAS 534-69-0|DC Chemicals

Cas No.:	534-69-0
Chemical Name:	erythro-5-Phosphooxy-L-lysine
Formula:	C₁₀H₁₇NO₉S₂
M.Wt:	359.37
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC71825	Chitosan oligosaccharide	Chitosan oligosaccharide (COS) is an oligomer of β-(1→4)-linked D-glucosamine. Chitosan oligosaccharide (COS) activates AMPK and inhibits inflammatory signaling pathways including NF-κB and MAPK pathways.
DC44584	TCEP Hydrochloride	TCEP (Tris(2-carboxyethyl)phosphine) hydrochloride, a non-thiol reducing agent, promotes NF-κB-DNA binding in a dose-related manner.
DC28670	DCZ0415	DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients.
DC28480	Urolithin B	Urolithin B is one of the gut microbial metabolites of ellagitannins, and has anti-inflammatory and antioxidant effects. Urolithin B inhibits NF-κB activity by reducing the phosphorylation and degradation of IκBα, and suppresses the phosphorylation of JNK, ERK, and Akt, and enhances the phosphorylation of AMPK. Urolithin B is also a regulator of skeletal muscle mass.
DC28410	B022	B022 represents a breakthrough in targeted kinase modulation as a highly potent and selective NF-κB-inducing kinase (NIK) antagonist.
DC8872	Iguratimod	Iguratimod is one of a series of 4H-1-benzopyran-4-ones which has potent anti-inflammatory, analgesic and antipyretic activity.
DC11926	NDMC101	A small molecule that inhibits NFATc1 and NF-κB activity, inhibits RANKL-induced osteoclastogenesis in vivo.
DC81099	Myristoleyl methane sulfonate	Myristoleyl methane sulfonate is a lipid.
DC81048	MiADMSA	MiADMSA (Monoisoamyl meso-2,3-dimercaptosuccinic acid) is an orally active thiol chelator that can effectively remove heavy metals such as arsenic and lead from the body of animals. Arsenic binds with two vicinal sulfhydryl groups available in MiADMSA leading to marked reduction in body arsenic burden and also marked reduction in various oxidative stress parameters and antioxidant enzymes like-ROS, nitrite, TBARS, GSH, SOD and catalase. MiADMSA attenuates urinary bladder carcinogenesis, protects against oxidative stress, ameliorates copper-induced histopathology, reverses neurotoxicity, and is safe in animals. MiADMSA can be used in studies of bladder cancer, arsenic, and lead-induced developmental neurotoxicity.
DC80878	JAK2-IN-16	JAK2-IN-16 (Compound Example 4) is a JAK2 V617F inhibitor. JAK2-IN-16 can be used for the research of cancer.